News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


PHARMAC steps up to help meet Government cancer treatment g

7 December 2012

Media release

PHARMAC steps up to help meet Government cancer treatment goal

Recent decisions by PHARMAC will have a positive effect on cancer treatment in New Zealand.

PHARMAC has removed the Special Authority funding requirements from seven cancer treatments, and from the diabetes treatment pioglitazone. Special Authorities define the clinical criteria patients must meet to receive some funded medicines. Clinicians must complete a Special Authority application and receive approval before prescribing in order for the patient to receive the funded medicine.

PHARMAC’s medical director Dr Peter Moodie, says the lifting of these funding restrictions is a positive step.

“Removing the Special Authorities from these cancer treatments will significantly reduce administrative demands on the hospital oncologists and haematologists who routinely prescribe these drugs,” says Dr Moodie.

“In addition, one of the medicines being de-restricted is capecitabine, a tablet which can be used in place of 5-flourouracil, a chemotherapy infusion that patients need to receive in hospitals or special treatment centres. Patients prescribed capecitabine will have a more convenient treatment option which they can take at home and this is particularly helpful for rural people and reduces their costs of receiving treatment.

“Removing the Special Authority restrictions will also free up hospital resources that can be used to treat more patients overall, which will help DHBs achieve the Government health priority to reduce cancer treatment waiting times.”

The medicines having Special Authority funding requirements removed are:

o Anagrelide hydrochloride – primarily used to treat thrombothycaemia (overproduction of platelets)

o Gemcitabine hydrochloride - used to treat a variety of cancers including bladder, breast, pancreas, lymphoma, lung and ovarian cancer.

o Irinotecan - primarily used to treat bowel and pancreatic cancer.

o Oxaliplatin - primarily used to treat bowel, pancreas and stomach cancer.

o Vinorelbine - primarily used to treat lymphoma, lung and breast cancer

o Capecitabine – primarily used to treat breast, bowel and stomach cancer

o Octreotide – primarily used in cancer for endocrine tumours and for palliation of symptoms in patients with malignant bowel obstruction.

Overall, removing the Special Authorities from these medicines will reduce the number of applications by about 4000 per year.

The Special Authorities were removed from these treatments from 1 December 2012 meaning that they are now fully funded by DHBs for any cancer patients. In addition, capecitabine is funded for any patient in the community when prescribed by a specialist.

Dr Moodie says that making access easier, such as by removing Special Authorities, usually results in more patients being prescribed the treatment.

“Effectively, this means we are giving doctors treating cancer greater discretion in how they choose to treat their patients, in the knowledge that it will be funded for them.”

Pioglitazone is a treatment that increases the body’s sensitivity to insulin, and is mainly used to treat Type 2 diabetes.

As with the cancer treatments, the Special Authority on pioglitazone was removed from 1 December.

ENDS


© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Scoop Review Of Books: Q&A: Prue Hyman On ‘Hopes Dashed?’

For Scoop Review of Books, Alison McCulloch interviewed Prue Hyman about her new book, part of the BWB Texts series, Hopes Dashed? The Economics of Gender Inequality More>>

Gordon Campbell: On Chuck Berry (And James Comey, And Bill English)

Back when many people were still treating rock’n’roll as a passing fad – was calypso going to be the new thing? – Chuck Berry knew that it had changed popular music forever. What is even more astonishing is that this 30-ish black r&b musician from a middle class family in St Louis could manage to recreate the world of white teenagers, at a time when the very notion of a “teenager” had just been invented. More>>

Howard Davis Review:
The Baroque Fusion Of L'arpeggiata

Named after a toccata by German composer Girolamo Kapsberger, L'Arpeggiata produces its unmistakable sonority mainly from the resonance of plucked strings, creating a tightly-woven acoustic texture that is both idiosyncratic and immediately identifiable. Director Christina Pluhar engenders this distinctive tonality associated with the ensemble she founded in 2000 by inviting musicians and vocalists from around the world to collaborate on specific projects illuminated by her musicological research. More>>

African Masks And Sculpture: Attic Discovery On Display At Expressions Whirinaki

Ranging from masks studded with nails and shards of glass to statues laden with magical metal, the works are from ethnic groups in nine countries ranging from Ivory Coast to the Democratic Republic of the Congo. More>>

Obituary: Andrew Little Remembers Murray Ball

“Murray mined a rich vein of New Zealand popular culture and exported it to the world. Wal and Dog and all the other Kiwi characters he crafted through Footrot Flats were hugely popular here and in Australia, Europe and North America." More>>

ALSO:

Organised Choas: NZ Fringe Festival 2017 Awards

Three more weeks of organised chaos have come to an end with the Wellington NZ Fringe Arts Festival Awards Ceremony as a chance to celebrate all our Fringe artists for their talent, ingenuity, and chutzpah! More>>

ALSO:

Wellington.Scoop: Wellington Writer Wins $US165,000 Literature Prize

Victoria University of Wellington staff member and alumna Ashleigh Young has won a prestigious Windham-Campbell Literature Prize worth USD$165,000 for her book of essays Can You Tolerate This? More>>

ALSO:

Scoop Review Of Books: We’re All Lab Rats

A couple of years ago, there were reports that Silicon Valley executives were sending their children to tech-free schools. It was a story that dripped of irony: geeks in the heart of techno-utopia rejecting their ideology when it came to their own kids. But the story didn’t catch on, and an awkward question lingered. Why were the engineers of the future desperate to part their gadgets from their children? More>>

  • CensusAtSchool - Most kids have no screen-time limits
  • Netsafe - Half of NZ high school students unsupervised online
  • Get More From Scoop

     
     

    LATEST HEADLINES

     
     
     
     
    Health
    Search Scoop  
     
     
    Powered by Vodafone
    NZ independent news